The HIV-1 integrase protein (IN) mediates integration of the viral cDNA into the host genome and is a target for anti-HIV drugs. We have recently described a peptide derived from residues 361-370 of the IN cellular partner protein LEDGF/p75, which inhibited IN catalytic activity in vitro and HIV-1 replication in cells. Here we performed a comprehensive study of the LEDGF 361-370 mechanism of action in vitro, in cells and in vivo. Alanine scan, fluorescence anisotropy binding studies, homology modeling and NMR studies demonstrated that all residues in LEDGF 361-370 contribute to IN binding and inhibition. Kinetic studies in cells showed that LEDGF 361-370 specifically inhibited integration of viral cDNA. Thus, the full peptide was chosen for in vivo studies, in which it inhibited the production of HIV-1 RNA in mouse model. We conclude that the full LEDGF 361-370 peptide is a potent HIV-1 inhibitor and may be used for further development as an anti-HIV lead compound.
|Original language||American English|
|Number of pages||6|
|Journal||Biochemical and Biophysical Research Communications|
|State||Published - 2 Apr 2010|
Bibliographical noteFunding Information:
This study was supported by a starting grant from the European Research Council (ERC) (to A.F.) and by Grants DA017618 and NS054580 from the National Institutes of Health, the US Public Health Service (to D.J.V.). We would like to thank G. Bentsman and D. Kim for technical help in animal experiments.
- Alanine scan
- Fluorescence anisotropy
- Homology modeling